Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Dow
Boehringer Ingelheim
Express Scripts
Merck

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Lebrikizumab

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Lebrikizumab: Sponsors, patents, clinical trial progress

Lebrikizumab is an investigational drug.

There have been 20 clinical trials for Lebrikizumab. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2013.

The most common disease conditions in clinical trials are Asthma, Dermatitis, and Eczema. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and Dermira, Inc.

There are ten US patents protecting this investigational drug and three hundred and twenty-seven international patents.

Recent Clinical Trials for Lebrikizumab
TitleSponsorPhase
A Study of Lebrikizumab in Patients With Moderate-to-Severe Atopic DermatitisDermira, Inc.Phase 2
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease (COPD)Hoffmann-La RochePhase 2
A Single-Arm Study to Evaluate Administration of Lebrikizumab by Participants or Caregivers in the Home SettingHoffmann-La RochePhase 3

See all Lebrikizumab clinical trials

Clinical Trial Summary for Lebrikizumab

Top disease conditions for Lebrikizumab
Top clinical trial sponsors for Lebrikizumab

See all Lebrikizumab clinical trials

US Patents for Lebrikizumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Lebrikizumab   See Pricing Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders Knopp Biosciences LLC (Pittsburgh, PA)   See Pricing
Lebrikizumab   See Pricing Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   See Pricing
Lebrikizumab   See Pricing Compositions and methods for treating chronic urticaria Knopp Biosciences LLC (Pittsburgh, PA)   See Pricing
Lebrikizumab   See Pricing Cholestosome vesicles for incorporation of molecules into chylomicrons THERASYN SENSORS, INC. (Eggertsville, NY)   See Pricing
Lebrikizumab   See Pricing Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   See Pricing
Lebrikizumab   See Pricing Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients Corning Incorporated (Corning, NY)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Lebrikizumab

Drugname Country Document Number Estimated Expiration Related US Patent
Lebrikizumab Australia 2014287067 2033-07-12   See Pricing
Lebrikizumab Australia 2014306597 2033-07-12   See Pricing
Lebrikizumab Australia 2014306683 2033-07-12   See Pricing
Lebrikizumab Australia 2017276231 2033-07-12   See Pricing
Lebrikizumab Canada 2918035 2033-07-12   See Pricing
Lebrikizumab Canada 2921378 2033-07-12   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Express Scripts
Boehringer Ingelheim
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.